Deamidation and isomerization liability analysis of 131 clinical-stage antibodies
Sign Up to like & getrecommendations! Published in 2019 at "mAbs"
DOI: 10.1080/19420862.2018.1548233
Abstract: ABSTRACT Contemporary in vivo and in vitro discovery platform technologies greatly increase the odds of identifying high-affinity monoclonal antibodies (mAbs) towards essentially any desired biologically relevant epitope. Lagging discovery throughput is the ability to select… read more here.
Keywords: clinical stage; isomerization liability; chemical stability; deamidation isomerization ... See more keywords